[go: up one dir, main page]

AR030121A1 - Derivados de benzimidazol, su preparacion y su aplicacion en terapeutica - Google Patents

Derivados de benzimidazol, su preparacion y su aplicacion en terapeutica

Info

Publication number
AR030121A1
AR030121A1 ARP010103751A ARP010103751A AR030121A1 AR 030121 A1 AR030121 A1 AR 030121A1 AR P010103751 A ARP010103751 A AR P010103751A AR P010103751 A ARP010103751 A AR P010103751A AR 030121 A1 AR030121 A1 AR 030121A1
Authority
AR
Argentina
Prior art keywords
optionally substituted
hydrogen atom
group
therapeutics
atom
Prior art date
Application number
ARP010103751A
Other languages
English (en)
Inventor
Francis Barth
Daniel Bichon
Frank Bolkenius
Dorsselaer Viviane Van
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0010419A external-priority patent/FR2812878B1/fr
Priority claimed from FR0014696A external-priority patent/FR2816619B1/fr
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of AR030121A1 publication Critical patent/AR030121A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)

Abstract

Derivados de benzimidazol de formula general (1) en la cual X representa un átomo de nitrogeno o un átomo de carbono; y en el caso en que X representa un átomo de nitrogeno: R3 representa un átomo de hidrogeno o un grupo alquilo (C1-4), o no existe, para dar los compuestos de formula (1) que presentan una amina secundaria o terciaria; R4 representa un átomo de hidrogeno o un grupo alquilo (C1-6), cicloalquilo (C3-7), heterocicloalquilo(C3-7), eventualmente sustituido, heteroarilo-(CH2)p-, heteroarilcarbonilo, fenilcarbonilo, alquilcarbonilo (C1-6), -(CH2)pCOOR, fenilsulfonilo eventualmente sustituido o-(CH2)p- fenilo eventualmente sustituido, y en el caso en que X representa un átomo de carbono: R3 representa un átomo de hidrogeno o un grupo ûNR5R6, -N(R5)3+, -NHCOR7, -CONHR5, COR7, -NHCONH2, -OH o ûCH2OH, R4 representa un átomo de hidrogeno o un grupo û(CH2)p-fenilo eventualmente sustituido, heteroarilo-(CH2)p- o û(CH2)t NR7R8. Los símbolos R1, R2, R2', R, R5, R6, R7, R8, n, m, p, t, tienen los significados asignados en la descripcion. Procedimiento de preparacion y aplicacion en terapéutica.
ARP010103751A 2000-08-08 2001-08-06 Derivados de benzimidazol, su preparacion y su aplicacion en terapeutica AR030121A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0010419A FR2812878B1 (fr) 2000-08-08 2000-08-08 Derives de benzimidazole, leur preparation et leur application en therapeutique
FR0014696A FR2816619B1 (fr) 2000-11-15 2000-11-15 Derives de benzimidazole, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
AR030121A1 true AR030121A1 (es) 2003-08-13

Family

ID=26212570

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010103751A AR030121A1 (es) 2000-08-08 2001-08-06 Derivados de benzimidazol, su preparacion y su aplicacion en terapeutica

Country Status (28)

Country Link
US (2) US6794382B2 (es)
EP (1) EP1309594B1 (es)
JP (1) JP2004505975A (es)
KR (1) KR20030020450A (es)
CN (1) CN1446218A (es)
AR (1) AR030121A1 (es)
AT (1) ATE284886T1 (es)
AU (1) AU2001282267A1 (es)
BG (1) BG107460A (es)
BR (1) BR0113046A (es)
CA (1) CA2412368A1 (es)
CZ (1) CZ294493B6 (es)
DE (1) DE60107859T2 (es)
EA (1) EA005950B1 (es)
EE (1) EE200300048A (es)
ES (1) ES2233671T3 (es)
HK (1) HK1053118A1 (es)
HR (1) HRP20030081A2 (es)
HU (1) HUP0301514A2 (es)
IL (1) IL153708A0 (es)
IS (1) IS6661A (es)
MX (1) MXPA03000753A (es)
NO (1) NO20030596L (es)
PL (1) PL365080A1 (es)
PT (1) PT1309594E (es)
SK (1) SK1582003A3 (es)
WO (1) WO2002012239A1 (es)
YU (1) YU7203A (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050119251A1 (en) * 2001-12-21 2005-06-02 Jian-Min Fu Nicotinamide derivatives and their use as therapeutic agents
US20040014744A1 (en) * 2002-04-05 2004-01-22 Fortuna Haviv Substituted pyridines having antiangiogenic activity
WO2003104233A1 (en) * 2002-06-07 2003-12-18 Altana Pharma Ag 4,5-dihydro-imidazo (4,5,1-ij) quinolin-6-ones derivatives and their use as poly (adp-ribosyl) transferase (parp) inhibitors
WO2003103666A2 (en) * 2002-06-07 2003-12-18 Altana Pharma Ag Novel 4,5-dihydro-imidazo[4,5,1-ij]quinolin-6-ones
WO2004108723A1 (en) * 2003-06-04 2004-12-16 Altana Pharma Ag 4,5-dihydro-imidazo[4,5,1-ii]quinolin-6-ones as parp inhibitors
GB0317466D0 (en) * 2003-07-25 2003-08-27 Univ Sheffield Use
DK1684736T3 (da) 2003-12-01 2011-11-21 Kudos Pharm Ltd Inhibitorer af DNA-skadereparation til behandling af cancer
AR051294A1 (es) * 2004-09-20 2007-01-03 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
TW200626139A (en) * 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
CN101083982A (zh) 2004-09-20 2007-12-05 泽农医药公司 用于治疗硬脂酰CoA去饱和酶介导的疾病的杂环衍生物
AU2005286728A1 (en) * 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
WO2006034440A2 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
US7829712B2 (en) * 2004-09-20 2010-11-09 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase
CN101084211A (zh) * 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其作为治疗剂的用途
CA2580860A1 (en) * 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Pyridine derivatives for inhibiting human stearoyl-coa-desaturase
WO2006034441A1 (en) * 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
JP2008526815A (ja) * 2005-01-11 2008-07-24 ノイロサーチ アクティーゼルスカブ 低コンダクタンスのカルシウム依存性カリウムチャネルのモジュレーターとしての新規２−アミノベンゾイミダゾール誘導体及びそれらの使用
EP2029138A1 (en) * 2005-06-03 2009-03-04 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
BRPI0614168A2 (pt) * 2005-08-05 2017-07-25 Astrazeneca Ab Composto ou um sal, hidrato, solvato, isoforma, tautômero, isômero óptico farmaceuticamente aceitável ou uma combinação dos mesmos, composição farmacêutica, método para o tratamento ou prevenção de distúrbios neurológicos e psquiátricos, uso de um composto, e, processo para a preparação de um composto
US20090239880A1 (en) * 2006-07-03 2009-09-24 Ulrik Svane Sorensen Combinations of monoamine reuptake inhibitors and potassium channel activators
GB0716532D0 (en) 2007-08-24 2007-10-03 Angeletti P Ist Richerche Bio Therapeutic compounds
GB201220157D0 (en) * 2012-11-08 2012-12-26 Selvita Sa Substitute tricyclic benzimidazoles as kinase inhibitors
CN103923088B (zh) * 2013-01-11 2016-09-07 上海汇伦生命科技有限公司 2,5-二氮杂双环[2.2.1]庚烷类化合物和制备方法、其药用组合物及其在医药上的应用
EP3581576B1 (en) 2013-03-15 2022-01-26 Incyte Holdings Corporation Tricyclic heterocycles as bet protein inhibitors for use in the treatment of a proliferative disease in combination with a janus kinase inhibitor
CN104230896A (zh) * 2013-06-17 2014-12-24 上海汇伦生命科技有限公司 苯并咪唑-2-哌嗪杂环类化合物、其药物组合物及其制备方法和用途
WO2015095492A1 (en) 2013-12-19 2015-06-25 Incyte Corporation Tricyclic heterocycles as bet protein inhibitors
TWI735002B (zh) 2014-04-23 2021-08-01 美商英塞特公司 作為BET蛋白抑制劑之1H-吡咯并[2,3-c]吡啶-7(6H)-酮及吡唑并[3,4-c]吡啶-7(6H)-酮
US10494380B2 (en) * 2015-05-29 2019-12-03 Shionogi & Co., Ltd. Nitrogen-containing tricyclic derivatives having HIV replication inhibitory activity
TWI786050B (zh) 2016-06-20 2022-12-11 美商英塞特公司 Ｂｅｔ抑制劑之結晶固體形式
CN110661676B (zh) * 2018-06-29 2022-06-28 大唐移动通信设备有限公司 一种带宽部分的测量方法、配置方法、终端及网络设备
CN111349094B (zh) * 2020-04-23 2021-02-02 杭州师范大学 一种6H-咪唑[4,5,1-ij]并喹诺酮及其合成方法和应用
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2710915B1 (fr) 1993-10-04 1995-11-24 Synthelabo Dérivés de pipéridine, leur préparation et leur utilisation en thérapeutique.
FR2731708B1 (fr) * 1995-03-13 1997-04-30 Synthelabo Derives de piperidine, leur procede de preparation et leur application en therapeutique
EP1133477B1 (de) * 1998-11-27 2004-02-18 Abbott GmbH & Co. KG Substituierte benzimidazole und ihre verwendung als parp inhibitoren

Also Published As

Publication number Publication date
MXPA03000753A (es) 2003-10-15
HRP20030081A2 (en) 2005-02-28
KR20030020450A (ko) 2003-03-08
NO20030596L (no) 2003-04-01
YU7203A (sh) 2006-01-16
SK1582003A3 (en) 2003-08-05
HK1053118A1 (en) 2003-10-10
US20030203893A1 (en) 2003-10-30
US20050032779A1 (en) 2005-02-10
ES2233671T3 (es) 2005-06-16
PL365080A1 (en) 2004-12-27
BR0113046A (pt) 2003-07-01
DE60107859D1 (de) 2005-01-20
AU2001282267A1 (en) 2002-02-18
EP1309594A1 (fr) 2003-05-14
ATE284886T1 (de) 2005-01-15
JP2004505975A (ja) 2004-02-26
EA005950B1 (ru) 2005-08-25
CN1446218A (zh) 2003-10-01
EE200300048A (et) 2004-12-15
WO2002012239A1 (fr) 2002-02-14
DE60107859T2 (de) 2005-12-22
CZ294493B6 (cs) 2005-01-12
CZ2003354A3 (cs) 2003-05-14
BG107460A (bg) 2003-09-30
US6794382B2 (en) 2004-09-21
IL153708A0 (en) 2003-07-06
HUP0301514A2 (hu) 2003-09-29
PT1309594E (pt) 2005-04-29
IS6661A (is) 2002-12-19
EP1309594B1 (fr) 2004-12-15
NO20030596D0 (no) 2003-02-06
EA200201259A1 (ru) 2003-06-26
CA2412368A1 (fr) 2002-02-14

Similar Documents

Publication Publication Date Title
AR030121A1 (es) Derivados de benzimidazol, su preparacion y su aplicacion en terapeutica
UY26958A1 (es) Nuevos agentes anticolinérgicos que se pueden emplear como medicamentos así como procedimiento para su preparación
CO5261488A1 (es) Indolinonas sustituidas en posiscion 6, su preparacion y utilizacion como medicamentos
UY26957A1 (es) Nuevos agentes anticolinérgicos que se pueden emplear como medicamentos así como procedimiento para su preparación
AR038723A1 (es) Cumarinas utiles como biomarcadores
AR042437A1 (es) Derivados de fluoroglicosidos heterociclicos, medicamentos que los contienen y usos
CO5150227A1 (es) Compuestos de triazol y su utilizacion
AR064730A1 (es) Derivados de 2,4-dianilinopirimidinas, su preparacion, composiciones farmaceuticas y usos como inhibidores de ikk
ES2130985B1 (es) Hidroxifeniltriazinas.
AR068386A1 (es) Derivados de 1,2,4,5-tetrahidro-3h-3-benzazepinas, su procedimiento de preparacion, composiciones farmaceuticas que los contienen y usos de los mismos en patologias asociadas a los canales hcn, tales como trastornos del aparato cardiovascular.
HN1999000156A (es) Aparatos electricos para ser montados sobre red
ATE399171T1 (de) Camptothecinanaloge und deren zubereitungsmethoden
ES2171923T3 (es) Profarmacos de la talidomida, su procedimiento de preparacion y su utilizacion como principios activos en medicamentos.
SV1999000059A (es) Compuestos farmaceuticos casa n.g. 1327
AR041697A1 (es) Piperazinil y diazepanil benzamidas y benzotiamidas; composiciones farmaceuticas que las contienen y su uso para la fabricacion de un medicamento
UY27244A1 (es) Uso del acido- (4´-trifluormetilfenil) - amida (z) -2- ciano-3- hidroxi-but-2-enoico para el tratamiento de la esclerosis multiple
DK1181294T3 (da) Hidtil ukendte derivater og analoger af galanthamin
HN2002000110A (es) Uso de (z) - 2 - ciano - 3 - hidroxi - butil - 2 - acido enoico (4' - trifluorometil fenilo) - amida para el tratamiento de la esclerosis multiple.
CR8340A (es) Pirazolilcarboxanilidas n-sustituidas
TR200200360T2 (tr) Antibakteriyel aktif maddeler.
ITMC20010029U1 (it) Placca chirurgica anti-trauma per il fissaggio di monconi mandibiolari
AR025638A1 (es) Conjugados de glucopiranosidas de 2-(4-hidroxi-fenil)-3-metil-1-/4-(2-amin-1-il-etoxi)-bencil/-1h-indol-5-oles
AR037123A1 (es) Compuestos sustituidos de 1h-quinoxalin-2-ona; metodo de preparacion del compuesto y medicamento que lo contiene
SV2004001370A (es) Compuestos basicos lineales que tienen actividad antagonista de nk-2 y sus formulaciones
EA200101230A1 (ru) Новые ингибиторы металлопротеаз, метод их получения и содержащие их фармацевтические композиции

Legal Events

Date Code Title Description
FA Abandonment or withdrawal